InsiderTrades

Form 4 for SPRY ARS Pharmaceuticals, Inc.

Accepted 2025-03-07 00:00:00 ET · period of report 2025-03-05 · accession 0001415889-25-007438 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2025-03-07 2025-03-05+ SPRY Shawver Laura Dir M - OptEx $4.85 +50.0K 259.9K +24% +$242.5K
DM 2025-03-07 2025-03-05+ SPRY Shawver Laura Dir S - Sale+OE $11.21 -50.0K 210.3K -19% -$560.4K
DM 2025-03-07 2025-03-05+ SPRY Shawver Laura Dir M - OptEx $0.00 -50.0K 123.7K -29% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-03-05 M A 400 $4.85 210,746 D — —
2 Common Common Stock 2025-03-06 S D 49,600 $11.21 210,346 D — — (F2) The weighted average sale price for the transaction reported was $11.2106 and the range of prices were between $11.00 and $11.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
3 Common Common Stock 2025-03-06 M A 49,600 $4.85 259,946 D — —
4 Common Common Stock 2025-03-05 S D 400 $11.00 210,346 D — —
5 Derivative Stock Option (Right to Buy) 2025-03-06 M D 49,600 $0.00 74,064 D $4.85 · — to 2032-01-31 49,600 Common Stock (F3) Immediately exercisable.
6 Derivative Stock Option (Right to Buy) 2025-03-05 M D 400 $0.00 123,664 D $4.85 · — to 2032-01-31 400 Common Stock (F3) Immediately exercisable.